FDA has concluded there is an increased risk of death with Uloric (febuxostat) compared to another gout medicine, allopurinol. This conclusion is based on our in-depth review of results from a safety clinical trial that found an increased risk of heart-related death and death from all causes with Uloric.
It's named after a woman, Lavern Wilkinson, who died in 2013 of treatable lung cancer. Her radiologist noticed a suspicious mass in 2010, but Lavern was never told. When she went back more than 2½ later for a chronic cough, she was told she had cancer, that it had spread, and that it was terminal.